NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
On Monday, NovoCure Ltd (NASDAQ:NVCR) and Zai Lab Limited (NASDAQ:ZLAB) revealed topline data from the Phase 3 PANOVA-3 trial of Tumor-Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable,
Novocure therapy succeeds in pancreatic cancer trial
Novocure (NASDAQ:NVCR) has met the primary endpoint of overall survival in a late-stage trial evaluating the use of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer. Shares of the oncology company jumped 25% premarket on Monday.
NovoCure’s TTFields Therapy Shows Promise in PANOVA-3 Trial
Novocure’s Phase 3 PANOVA-3 trial has shown promising results in treating unresectable, locally advanced pancreatic cancer with Tumor Treating Fields (TTFields) therapy, improving median overall survival by 2 months compared to standard treatment.
Novocure Shares Jump 26% on Trial Results for Pancreatic Cancer Therapy
Novocure shares jumped 26% in premarket trading following trial results of a therapy for pancreatic cancer. Shares were trading around $25.22. The stock is up 34% on the year. The oncology company and Zai Lab,
Novocure Stock Soars On Positive Pancreatic Cancer Trial Results, Retail Sentiment Surges
Shares of Novocure Ltd. skyrocketed over 55% on Monday afternoon, reaching levels last seen in August 2023, as the company announced promising Phase 3 trial results for its Tumor Treating Fields (TTFields) therapy.
Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields
Novocure’s positive phase 3 results boost pancreatic cancer treatment prospects. Read why NVCR stock is worth watching with upcoming studies in 2025 and 2026.
Drug Store News22d
Sandoz launches generic paclitaxel in single-dose vial
Sandoz is offering a generic paclitaxel formulation, which is the first FDA-approved ANDA to BioScience’s Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable ...
Outsourcing-pharma7h
Novocure reports positive phase 3 results for tumor treating fields therapy
Novocure's PANOVA-3 trial shows TTFields therapy with chemotherapy improves survival in pancreatic cancer, marking a ...
Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint
Zai Lab (ZLAB) and Novocure (NVCR) announced that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating ...
Novocure announces PANOVA-3 trial met primary endpoint
Novocure (NVCR) announced that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant ...
Nature5y
Paclitaxel-based therapy no better than cisplatin and 5-FU for operable esophageal cancer
Kelsey et al. compared the common chemotherapeutic combination of cisplatin and fluorouracil (5-FU) with a paclitaxel-based regimen. Previous studies have shown pathologic complete response rates ...
TCTMD1mon
Paclitaxel, Sirolimus, Biolimus: The Art of DCBs Selection
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...
Medscape4y
Paclitaxel-Coated Devices on Pause for Patients With PAD
Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...
GlobalData on MSN1d
Novocure seeks approval after pancreatic cancer wearable scores at Phase III
Novocure’s TTFields therapy combined with chemo improved overall survival by 16.2 months compared to 14.16 months with chemo ...
TCTMD1mon
TCT 41: Paclitaxel-Coated Versus Sirolimus-Coated Balloon Angioplasty for Coronary Artery Disease: A Systematic Review and Meta-Analysis
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...